Alere began recalling lots of Alere's Triage products following reports of decreased precision leading to false positive and false negative results. The recall includes Triage CardioProfiler Panel , Triage Cardiac Panel , Triage Profiler SOB Panel , Triage...

By Stacy Lawrence Senior Writer OSI Pharmaceuticals Inc. (NASDAQ:OSIP) isn't talking about what happened during its search for buyers, but it looks like the White Knight investors hoped for never showed. Almost two months after...

Inverness' Biosite Inc. subsidiary voluntarily recalled one lot of its Triage Cardiac Panel to diagnose myocardial infarction. Biosite said quality control testing of the lot showed low recovery of creatine kinase MB , troponin I and...

Adnavance Technologies Inc. , Vancouver, B.C.   Business: Supply/Service, Diagnostic   Appointed: Kenneth Buechler, former president of Inverness Medical Innovations Inc. 's Biosite Inc. subsidiary  ...

Inverness' Biosite Inc. subsidiary will develop and select antibodies that bind to Compugen's CGEN-144 , a variant of troponin 1. Troponin 1 is a biomarker used to diagnose myocardial infarction (MI). Biosite received an option to...

Oxford Genome Sciences Ltd. has done two deals in the last few months that should enable it to realize management's vision of transitioning from a biomarker services business into a therapeutics company by leveraging targets...

Quidel Corp. (QDEL), San Diego, Calif.   Business: Diagnostic   Appointed: Kenneth Buechler, formerly president and CSO of Biosite Inc.  ...

Oxford Genome received access to MEDX's UltiMAb Human Antibody Development System to generate human therapeutic antibodies against cancer targets identified using the Oxford Genome Anatomy Project (OGAP) database. Oxford Genome will have exclusive, worldwide rights...

IMA completed its tender offer to acquire the BSTE shares that it did not already own for $92.50 per share in cash (see BioCentury, May 21). Biosite Inc. (BSTE), San Diego, Calif.   Inverness Medical...

Molecular diagnostics companies have demonstrated robust growth in the last few years and as a result two of the four leading companies are being acquired. As with therapeutic companies, the question is whether as any...